



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

FEB 26 2009

Re: Entereg
Patent Nos. 5,250,542 and 5,434,171
Docket Nos. FDA-2009-E-0073
and FDA-2009-E-0015

The Honorable Jon Dudas
Under Secretary of Commerce for Intellectual Property
Director of the United States Patent and Trademark Office
Mail Stop Hatch-Waxman PTE
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Dudas:

This is in regard to the applications for patent term extension for U.S. Patent Nos. 5,250,542 and 5,434,171 filed by Eli Lilly and Company, under 35 U.S.C. § 156. The human drug product claimed by the patents is Entereg-5,250,542 (alvimopan), which was assigned new drug application (NDA) No. 21-775.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1), and interpreted by the courts in *Glaxo Operations UK Ltd. v. Quigg*, 706 F. Supp. 1224 (E.D. Va. 1989), *aff'd*, 894 F. 2d 392 (Fed. Cir. 1990).

The NDA was approved on May 20, 2008, which makes the submission of the patent term extension application on June 17, 2008, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the *Federal Register*, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,


Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: Donald J. Bird
Morgan, Lewis & Bockius LLP
Customer # 09629
1111 Pennsylvania Avenue, N.W.
Washington, DC 20004